Fipravirimat

Fipravirimat
Clinical data
Other namesGSK3640254
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • (1R)-4-[(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethylamino]-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,11,11b,12,13,13a,13b-tetradecahydrocyclopenta[a]chrysen-9-yl]-1-(fluoromethyl)cyclohex-3-ene-1-carboxylic acid
CAS Number
PubChem CID
UNII
KEGG
Chemical and physical data
FormulaC43H67FN2O4S
Molar mass727.08 g·mol−1
3D model (JSmol)
SMILES
  • CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4(CC=C(C5(C)C)C6=CC[C@@](CC6)(CF)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7
InChI
  • InChI=1S/C43H67FN2O4S/c1-29(2)31-12-19-43(45-22-23-46-24-26-51(49,50)27-25-46)21-20-40(6)33(36(31)43)8-9-35-39(5)15-13-32(38(3,4)34(39)14-16-41(35,40)7)30-10-17-42(28-44,18-11-30)37(47)48/h10,13,31,33-36,45H,1,8-9,11-12,14-28H2,2-7H3,(H,47,48)/t31-,33+,34-,35+,36+,39-,40+,41+,42+,43-/m0/s1
  • Key:YFSNREBZTKMFEB-DHGHKPCRSA-N

Fipravirimat is an experimental drug for the treatment of HIV/AIDS. It belongs to a class of drugs known as maturation inhibitors.[1][2]

Fipravirimat is being developed by ViiV Healthcare and as of 2023 is in Phase II clinical trials.[3][4]

See also

References

  1. ↑ "Fipravirimat". PubChem. U.S. National Library of Medicine.
  2. ↑ Dicker I, Jeffrey JL, Protack T, Lin Z, Cockett M, Chen Y, et al. (January 2022). "GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile". Antimicrobial Agents and Chemotherapy. 66 (1): e0187621. doi:10.1128/AAC.01876-21. PMC 8765437. PMID 34780263.
  3. ↑ "Fipravirimat". AdisInsight. Springer Nature Switzerland AG.
  4. ↑ "ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV" (Press release). GSK. March 9, 2021.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.